Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvon Protection Regulatory News (AVON)

Share Price Information for Avon Protection (AVON)

Share Price is delayed by 15 minutes
Get Live Data
1,730.00    0.00 (0.00%)
Bid:
1,718.00
Ask:
1,726.00
Spread: 8.00 (0.466%)
Market Cap: £509.51m
AVON Live PriceLast checked at - London Stock Exchange

Intraday Avon Protection Share Chart

Trading Update

13 Aug 2021 07:00

RNS Number : 5232I
Avon Protection PLC
13 August 2021
 

13 August 2021

Avon Protection plc

Trading Update

 

Avon Protection plc ("Avon") today provides the following trading update for its current financial year ending 30 September 2021 ("FY21").

 

Trading update

 

Avon has continued to see good commercial progress in the second half of FY21, with order intake in the ten months to 31 July 2021 of $221m. This represents order growth, excluding Team Wendy, of 13% over the equivalent period last year, giving a strong order book of $146m (including Team Wendy), up 21% year-on-year. This progress has been driven by good results from the Team Wendy, First Responder and Military Respiratory lines of business.

 

Notwithstanding the positive demand backdrop, the impact of delays in the receipt of orders, supply chain disruption and a tight U.S. labour market has increased significantly through the second half of the financial year. Whilst this COVID-19 related disruption is expected to be temporary in nature, the impact has resulted in a reduction in our revenue guidance for FY21 to between $245m - $260m, due to:

 

· Delayed receipt of c.$16m of expected orders under existing contracts, including a significant M50 order, as a result of procurement bottlenecks;

 

· Extended lead times for predominantly electronic and textile components delaying the shipment of c.$6m of deliveries under existing orders; and

 

· Remaining uncertainties as to the timing of receipt of other orders that we expect to receive and ship before the end of the financial year.

 

The result of the lower revenue expectations, combined with an adverse mix effect and an overhead base that is fixed in the short term, means that adjusted EBITDA margin guidance is expected to reduce to between 17% - 18% for FY21, before recovering thereafter.

 

The Board is confident that the delayed orders will be received over the coming months, but expects supply chain disruption and a tight U.S. labour market to persist into next year. As a result, the Board believes it is prudent to take this into account and reduce FY22 revenue expectations to $320m - $340m, whilst maintaining current guidance for FY23.

 

The delays to product shipments have also resulted in a build-up of inventory and delayed receipts from customers which is likely to persist through the year end, with FY21 cash conversion now expected to be c.50%, based on the above revenue assumptions. Longer term cash flow dynamics continue to be strong, and the inventory position is expected to largely unwind through FY22.

 

Contract update

 

Considerable further progress has been made in respect of the delayed product approvals in the Military Ballistic business, in line with the Board's previous guidance. First Article Testing for the DLA ESAPI contract is well advanced, with initial shipments expected in the first half of FY22. Sample plates for the VTP ESAPI contract are on track to be delivered in September for testing, with initial shipments expected in the second half of FY22.

 

Avon has received a further $9m delivery order under the sole source first generation IHPS helmet contract, in addition to the $19m order already received in March. The procurement process to put in place a revised, multi-source next generation IHPS contract is well advanced and is expected to conclude before the end of September.

 

Commenting, Paul McDonald, Chief Executive Officer, said:

 

"We have made considerable commercial progress over the last 18 months in building a broad portfolio of significant, multi-year contracts across the business, with the underlying demand momentum continuing, so the short-term disruption that we are seeing is unwelcome. These issues will be resolved over the coming months, but as they are affecting both our customers and suppliers simultaneously the situation has significantly limited our operating agility in the short term.

 

We remain as confident as ever about the medium-term prospects of Avon Protection, underpinned by a record order book, a growing and visible contract pipeline and world leading businesses and technologies. We will carry significant momentum into next year, which will also benefit from a strong ramp-up in the Ballistics business, and remain well set for growth in FY22 and beyond."

 

 

For further enquiries, please contact:

 

Avon Protection plc

 

Paul McDonald, Chief Executive Officer

01225 896 848

Nick Keveth, Chief Financial Officer

 

 

 

 

 

MHP Communications

 

Andrew Jaques

0203 128 8570

Charlie Barker

avonprotection@mhpc.com

Pete Lambie

Ailsa Prestige

 

 

Legal Entity Identifier: 213800JM1AN62REBWA71

Certain information contained in this announcement would have constituted inside information (as defined by Article 7 of Regulation (EU) No 596/2014) ("MAR") prior to its release as part of this announcement and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations.

Note to editors: 

Avon Protection plc is listed on the London Stock Exchange (LSE: AVON) and is a constituent of the FTSE 250 Index.

Avon Protection is an innovative technology group, which designs and produces life critical personal protection systems to maximise the performance and capabilities of its customers, with leading positions in the respiratory and ballistic protection markets for the world's militaries and first responders.

For further information, please visit our website www.avon-protection-plc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSFSESEEFSEDA
Date   Source Headline
16th May 20253:00 pmRNSNotification of change in particulars of director
15th May 20251:00 pmRNSHolding(s) in Company
7th May 202510:00 amRNSDirectors'/PDMR Shareholding
6th May 202512:00 pmRNS-RNotice of Results & Investor Presentation via IMC
11th Apr 20254:00 pmRNSHolding(s) in Company
8th Apr 202511:00 amRNSDirectors'/PDMR Shareholding
27th Mar 20252:00 pmRNSHolding(s) in Company
26th Mar 20257:00 amRNSQ2 trading update
20th Mar 202510:00 amRNSHolding(s) in Company
11th Mar 20255:00 pmRNSDirector/PDMR Shareholding
6th Mar 20253:00 pmRNSDirectors'/PDMR Shareholdings
4th Mar 20254:00 pmRNSHolding(s) in Company
3rd Mar 20257:00 amRNSNext Generation IHPS Delivery Order
14th Feb 20252:00 pmRNSDirectors'/PDMR Shareholding
11th Feb 20254:00 pmRNSHolding(s) in Company
7th Feb 20254:00 pmRNSFinal Dividend Currency Exchange Rate
5th Feb 20254:00 pmRNSDirectors'/PDMR Shareholdings
31st Jan 202512:00 pmRNSResult of AGM
31st Jan 20257:00 amRNSAGM Statement
27th Jan 20253:00 pmRNSHolding(s) in Company
9th Jan 20257:00 amRNSThales UK Contract Renewal
7th Jan 20259:00 amRNSDirectors'/PDMR Shareholding
6th Jan 20257:00 amRNSNext Generation IHPS Delivery Order
12th Dec 20242:00 pmRNSHolding in Company
10th Dec 20249:00 amRNSNotice of Annual Report & Accounts and AGM 2025
6th Dec 202411:00 amRNSDirectors'/PDMR Shareholding
28th Nov 20245:00 pmRNSDirector/PDMR Shareholding
19th Nov 20242:00 pmRNSDirector/PDMR Shareholding
19th Nov 20247:00 amRNSPreliminary Results
6th Nov 20242:00 pmRNSHolding in Company
6th Nov 202410:00 amRNSDirectors'/PDMR Shareholding
25th Oct 202411:05 amRNSAppointment of Joint Corporate Broker
22nd Oct 20247:00 amRNSNotice of Results
8th Oct 202410:00 amRNSDirectors'/PDMR Shareholding
2nd Oct 20243:05 pmRNSHolding(s) in Company
26th Sep 20246:05 pmRNSHolding(s) in Company
10th Sep 20243:30 pmRNSDirector/PDMR Shareholding
15th Aug 20247:00 amRNSInterim Dividend Currency Exchange Rate
7th Aug 20249:00 amRNSDirectors'/PDMR Shareholdings
1st Aug 20248:19 amRNSChange of Company Name
1st Aug 20247:00 amRNSHolding(s) in Company
29th Jul 202412:00 pmRNSPDMR Shareholdings
25th Jul 20247:00 amRNSNew delivery order & updated FY 2024 guidance
10th Jul 20249:00 amRNSNotification of transaction of PDMR
8th Jul 202412:00 pmRNSDirectors'/PDMR Shareholdings
6th Jun 20243:00 pmRNSDirectors'/PDMR Shareholdings
30th May 20245:00 pmRNSHolding(s) in Company
28th May 20245:00 pmRNSHolding(s) in Company
24th May 20244:00 pmRNSHolding(s) in Company
21st May 20247:04 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.